John Partridge, Partner and Co-Chair of the FDA and Health Care Practice Group, shared insights with the Financial Times’ Agenda on the significance of robust internal reporting systems in corporations. He emphasized their importance amid changing corporate enforcement priorities.
Partridge highlighted that public companies face challenges due to differing whistleblower programs across jurisdictions. He stated, “all the more important to have a well-resourced internal reporting and investigation function.”
He further explained that such measures assist companies in detecting and addressing misconduct internally. This proactive approach can prevent issues from escalating to a level where external whistleblower programs become involved. Partridge noted, “This will help public companies to identify and remediate misconduct before it metastasizes to the point of driving someone to report to a whistleblower program.”
